Edelweiss Business Cycle Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?

Edelweiss Business Cycle Fund Direct Growth Plan has a NAV of ₹9.4365 as of 10 Sep 2026 and scheme AUM of ₹1,463 Cr. Its 1-year, 3-year and 5-year returns are 5.55%, 0.00% and 0.00%, and it sits in the High Risk category.

Our view is that the fund suits investors who can tolerate higher volatility and want an equity strategy that is still building a track record. The portfolio has a meaningful tilt toward healthcare, banking, industrials and financials, which can make returns more uneven than a plain benchmark-style allocation.

Quick facts

Particular	Details
NAV	₹9.4365 as of 10 Sep 2026
AUM	₹1,463 Cr
Expense Ratio	0.48%
Launch Date	29 Jul 2024
Min SIP	₹100
Risk Category	High Risk
Benchmark	Nifty 50
Fund Category	Equity
Exit Load	1% on or before 90D, Nil after 90D
Fund Managers	Bhavesh Jain, Bharat Lahoti, Amit Vora

The fund is managed by Bhavesh Jain, Bharat Lahoti and Amit Vora.

Source data date: as of 10 Sep 2026

Performance

Period	Fund return	Benchmark return
1M	-0.08%	-4.06%
3M	8.10%	1.37%
1Y	5.55%	-7.31%
3Y	Data not available	Data not available
5Y	Data not available	Data not available

The near-term pattern is better than the benchmark. Over 1 month, the fund stayed close to flat while the benchmark fell more sharply. Over 3 months, the fund moved ahead with a clear gain, which suggests it recovered faster than the benchmark from recent weakness.

The 1-year figure is the most useful anchor today because it shows positive return at a time when the benchmark is still negative. That gap tells us the fund has handled the recent cycle better than the index, even though the absolute return is still modest for an equity strategy.

What matters, though, is that the fund is young and does not yet have 3-year or 5-year return history to test whether this recent strength is durable. Our view is that the short record makes the current numbers helpful, but not enough on their own to judge how it may behave across a full market cycle.

The return path also looks uneven rather than smooth. That kind of movement is common in an actively oriented equity fund, and it reinforces the High Risk label for investors who prefer consistency.

Source data date: as of 10 Sep 2026

Should you BUY or HOLD Edelweiss Business Cycle?

A fund's past returns alone don't tell you whether you should buy it today or continue holding it.

The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.

Already holding Edelweiss Business Cycle? Thinking of investing now?

Get your portfolio analysed for FREE by SEBI-registered Investment Adviser (RIA) through Univest MF Premium

Peer comparison

Fund	1Y return	3Y return	5Y return
Edelweiss Business Cycle Fund Direct Growth Plan	5.55%	Data not available	Data not available
ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan	73.94%	37.12%	Data not available
Motilal Oswal Active Momentum Fund Direct Growth Plan	29.94%	Data not available	Data not available
Kotak Healthcare Fund Direct Growth Plan	29.26%	Data not available	Data not available
HDFC Pharma and Healthcare Fund Direct Growth Plan	28.30%	Data not available	Data not available
SBI Automotive Opportunities Fund Direct Growth Plan	27.13%	Data not available	Data not available

This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639. The fund’s 1-year return trails the five peer funds listed here, while the current fund’s own recent figure is still positive. Because the fund does not yet have 3-year or 5-year history, the comparison is driven more by short-term momentum than by long-cycle consistency. That makes the recent relative gap important, but it also limits how far we can stretch the conclusion.

Source data date: as of 10 Sep 2026

Portfolio: where your money goes

Holding	Sector	Weight
Laurus Labs Ltd.	Healthcare	4.19%
Cummins India Ltd.	Automobile & Ancillaries	3.64%
Polycab India Ltd.	Electricals	3.46%
State Bank of India	Bank	2.77%
Glenmark Pharmaceuticals Ltd.	Healthcare	2.76%
Ge Vernova T&D India Limited	Capital Goods	2.69%
Muthoot Finance Ltd.	Finance	2.41%
The Federal Bank Ltd.	Bank	2.34%
Sun Pharmaceutical Industries Ltd.	Healthcare	2.32%
Fortis Healthcare Ltd.	Healthcare	2.27%

The largest holding, Laurus Labs Ltd., is 4.19%, which is meaningful but not oversized for an equity fund. The drop from the first holding to the tenth is modest rather than steep, moving from 4.19% to 2.27%, so the top positions are relatively close in weight.

The top 10 holdings account for approximately 28.85% of the portfolio, which means most of the fund is spread across a broader set of positions. That structure may reduce dependence on any single stock, while still allowing the listed holdings to influence returns through healthcare, banking, industrial and financial exposure.

With 61 disclosed holdings in total, the fund appears to use a fairly extended tail beyond the top names. That usually points to a portfolio that is not narrowly concentrated, although the visible leaders can still matter because several of them sit in the 2% to 4% range.

To see all holdings, visit the Edelweiss Business Cycle Fund Direct Growth Plan page

Source data date: as of 10 Sep 2026

Who should invest

This fund is better suited to investors who are comfortable with High Risk equity exposure and can stay invested through uneven short-term moves. The current record is encouraging versus the benchmark, but the absence of 3-year and 5-year history means the longer test is still pending.

It may fit a medium- to long-term horizon where an investor can accept that recent strength may not repeat every year. The main trade-off is that the portfolio may participate well when its selected sectors work, but it can also behave more unevenly than a broad market fund.

Tax and exit load

Holding period	Tax rate	Description
Units held less than 1 year	20%	Short-term capital gains tax
Units held more than 1 year	12.5%	Long-term capital gains tax

Exit load: 1% on or before 90D, Nil after 90D.

Source data date: as of 10 Sep 2026

Frequently asked questions

What is the current NAV of Edelweiss Business Cycle Fund Direct Growth Plan?

The current NAV is ₹9.4365 as of 10 Sep 2026.

What are the 1-year, 3-year and 5-year returns?

The 1-year return is 5.55%, while the 3-year and 5-year returns are Data not available because the fund does not yet have those full histories.

How has the fund performed versus Nifty 50?

The fund has done better than Nifty 50 over the recent 1-month, 3-month and 1-year periods. The benchmark is still negative over 1 year, while the fund is positive.

How does it compare with the peer funds listed here?

Its 1-year return is lower than the peer funds listed here, while the fund’s own short history means 3-year and 5-year comparisons are not yet available for it.

What is the minimum SIP amount?

The minimum SIP amount is ₹100.

Who manages the fund and what is the exit load?

The fund is managed by Bhavesh Jain, Bharat Lahoti and Amit Vora. The exit load is 1% on or before 90 days and nil after 90 days.

Bottom line

The fund’s recent return profile is better than the benchmark, but it still lacks a long history to prove consistency across market cycles. Compared with the peer set listed here, its 1-year figure is lower, so the short-term picture is less compelling than the broader peer numbers. The portfolio is spread across 61 holdings, with no single position dominating, which may help limit concentration. For investors who can accept High Risk equity exposure and are comfortable with an evolving track record, the fund looks more like a watchlist candidate than a mature core holding.

Published on 11 September 2026 at 3:27 PM IST

Explore mutual funds with Univest

Review mutual fund data, compare performance and explore fund insights on Univest.

Explore Univest

RIA disclosure

Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.